z-logo
open-access-imgOpen Access
Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists
Author(s) -
Laurence Klotz
Publication year - 2012
Publication title -
canadian urological association journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.477
H-Index - 38
eISSN - 1920-1214
pISSN - 1911-6470
DOI - 10.5489/cuaj.70
Subject(s) - sunitinib , sorafenib , medicine , kidney cancer , systemic therapy , cancer , oncology , pharmacology , breast cancer , hepatocellular carcinoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom